Platform Changelog

Tool Invocation Mode Optimization

• Added Auto Mode: once enabled, users only need to provide the required parameters in the conversation. The platform can identify key information and invoke lightweight tools automatically, reducing repetitive form filling and manual submission.
• Form Mode remains available and can be switched on as needed. In Form Mode, each tool invocation still requires manual confirmation before execution, helping users review inputs before running a tool.

Credit System Optimization

• Optimized credit earning and spending rules for Personal users: users receive 20 same-day credits upon their first daily login, and can earn 50 permanent credits for approved case submissions or successful new-user referrals.
• After the free usage quota for lightweight tools is exceeded, each additional tool run consumes 5 credits. Developability assessment from the candidate list consumes 5 credits per antibody.

R&D Document Generation Launched

• The platform now supports target research, literature analysis, invention disclosures, and project summary reports. It can gather information, run tool-assisted analyses, and generate editable documents to accelerate early-stage research and capture project findings.

Candidate List Management and Developability Risk Analysis

• Added candidate list management, allowing researchers to consolidate antibody sequences into a single list for comparison, tracking, and follow-up analysis.
• Added five-dimensional developability risk analysis covering aggregation, chemical liabilities, humanness, polyreactivity, and viscosity to help assess sequence-level risks and support candidate selection and optimization.

Antibody Design Workflow Upgrades

• Added a CDR diversity engineering workflow, supporting sequence- and structure-pattern-based antibody optimization to expand AI-assisted antibody engineering capabilities.
• Upgraded the affinity maturation workflow to support key constraint-site configuration for more flexible, targeted optimization.

AI Agent Capability Upgrade

• Added multi-step task planning, enabling AI agents to break down R&D goals into tasks, plan workflows, and execute them continuously for more complex antibody design and analysis.

Click.mAb. V3.0 Officially Launched

The new AI antibody R&D collaboration platform is now officially launched. Built around project spaces, research goals, and AI agent interactions, the platform enables individual researchers and teams to conduct antibody design, analysis, and collaboration through natural language. It provides several core antibody R&D capabilities, including:

• Epitope-specific de novo antibody design
• Antibody affinity maturation
• Antibody humanization
• Nanobody humanization
• Epitope prediction
• Lightweight tools for antibody analysis and visualization

The platform also supports structured management and visualization of computational results, including antibody sequence analysis, structural model display, and design result comparison, helping researchers better understand computational outputs and advance subsequent research.